The Claim

Liraglutide 3.0 mg administered to obese non-diabetic adults over 1 year is associated with nausea and vomiting as common side effects, with 48% experiencing nausea and 13% vomiting; most episodes are mild (73% of nausea) or moderate and transient, with onset during the first 4-6 weeks of dose escalation, and only 4% of participants withdraw due to these events.

Source: Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
87score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

In a one-year study of obese non-diabetic adults taking liraglutide 3.0 mg, 48% experienced nausea and 13% experienced vomiting. Most nausea episodes (73%) were mild, and symptoms were temporary, starting during the first 4-6 weeks of dose increases. Only 4% of participants stopped treatment because of these side effects.

See the scientific wording

Nausea and vomiting are common side effects of liraglutide 3.0 mg in obese non-diabetic adults, occurring in 48% and 13% of participants respectively over 1 year, but symptoms are mostly mild (73% of nausea episodes) or moderate, and transient, with onset primarily during the first 4-6 weeks of dose escalation; only 4% of participants withdraw due to these events.

Why this might work

Liraglutide activates GLP-1 receptors on brainstem neurons that control nausea and vomiting. These neurons trigger the vomiting reflex when activated, especially during dose escalation when the drug levels rise quickly. The body adapts over time, so the nausea becomes less severe and goes away after a few weeks.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

    The study found that about half of people taking the highest dose of liraglutide felt nauseous and one in eight vomited, but these problems were usually mild and went away after a few weeks, with very few people quitting because of them.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.